Health ❯ Regulatory Affairs ❯ FDA

Drug Approval Process

Orphan Drug Designation Therapy Evaluation Patient Safety New Drug Application Recall Procedures Benefit-Risk Assessment Clinical Trial Outcomes Safety Warnings

FDA Staff Flags Major Flaws in Capricor’s Deramiocel Data

An independent advisory committee will decide on July 29 whether the trial evidence gives regulators enough reason to approve the cell therapy.

Fulcrum Halts Pociredir Development After FDA Flags PRC2 Cancer Risk